These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

684 related items for PubMed ID: 21097693

  • 1. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB.
    Clin Cancer Res; 2011 Feb 15; 17(4):783-91. PubMed ID: 21097693
    [Abstract] [Full Text] [Related]

  • 2. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    Mol Pharm; 2018 Jul 02; 15(7):2742-2753. PubMed ID: 29750868
    [Abstract] [Full Text] [Related]

  • 3. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    Lancet Oncol; 2015 Jan 02; 16(1):87-97. PubMed ID: 25481791
    [Abstract] [Full Text] [Related]

  • 4. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A.
    Lancet; 2010 Jul 24; 376(9737):245-51. PubMed ID: 20609468
    [Abstract] [Full Text] [Related]

  • 5. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    Expert Opin Investig Drugs; 2016 Jul 24; 25(5):597-611. PubMed ID: 26899229
    [Abstract] [Full Text] [Related]

  • 6. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
    Sui H, Shi C, Yan Z, Li H.
    Drug Des Devel Ther; 2015 Jul 24; 9():3183-90. PubMed ID: 26124641
    [Abstract] [Full Text] [Related]

  • 7. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.
    Lancet Oncol; 2011 Sep 24; 12(9):852-61. PubMed ID: 21862407
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ, Walters Haygood CL, Arend RC, Leath CA, Straughn JM.
    Gynecol Oncol; 2015 Oct 24; 139(1):59-62. PubMed ID: 26303225
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
    Chen Y, Zhang L, Hao Q.
    Arch Gynecol Obstet; 2013 Aug 24; 288(2):367-74. PubMed ID: 23619942
    [Abstract] [Full Text] [Related]

  • 13. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
    Gunderson CC, Moore KN.
    Future Oncol; 2015 Aug 24; 11(5):747-57. PubMed ID: 25757679
    [Abstract] [Full Text] [Related]

  • 14. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN, Monk BJ.
    Oncologist; 2016 Aug 24; 21(8):954-63. PubMed ID: 27256873
    [Abstract] [Full Text] [Related]

  • 15. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R, Gourley C.
    Expert Rev Anticancer Ther; 2016 Jun 24; 16(6):597-603. PubMed ID: 27115428
    [Abstract] [Full Text] [Related]

  • 16. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V, Illuzzi G, Héberlé E, Dantzer F.
    Bull Cancer; 2015 Oct 24; 102(10):863-73. PubMed ID: 26384693
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE, Ledermann JA.
    Clin Adv Hematol Oncol; 2016 Aug 24; 14(8):619-27. PubMed ID: 27487106
    [Abstract] [Full Text] [Related]

  • 20. [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, Bubien V, Garbay D, Joly E, Guyon F.
    Bull Cancer; 2014 Feb 24; 101(2):167-74. PubMed ID: 24555961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.